Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Cancer Res. 2014 Sep 1;20(17):4499–4510. doi: 10.1158/1078-0432.CCR-14-0348

Figure 3. LCS6-variant patients do not have improved OS with the addition of chemotherapy for all patients.

Figure 3

(A) Median overall survival (OS) according to the KRAS 3′-UTR LCS6 SNP genotype status in all patients treated with anti-EGFR moAbs monotherapy as salvage treatment. (B) Median OS according to the KRAS 3′-UTR LCS6 SNP genotype status in all patients treated with anti-EGFR moAbs based combination chemotherapy as salvage treatment. (C) Median OS according to type of therapy in all KRAS 3′-UTR LCS6 SNP carriers. (D) Median OS according to type of therapy in all non-KRAS 3′-UTR LCS6 SNP carriers.